Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Consolidated Net Income (2017 - 2025)

Sutro Biopharma's Consolidated Net Income history spans 9 years, with the latest figure at -$49.2 million for Q3 2025.

  • For Q3 2025, Consolidated Net Income fell 0.84% year-over-year to -$49.2 million; the TTM value through Sep 2025 reached -$203.0 million, down 63.74%, while the annual FY2024 figure was -$227.5 million, 112.98% down from the prior year.
  • Consolidated Net Income for Q3 2025 was -$49.2 million at Sutro Biopharma, down from -$11.5 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $31.1 million in Q4 2023 and bottomed at -$72.4 million in Q4 2024.
  • The 5-year median for Consolidated Net Income is -$38.5 million (2023), against an average of -$36.0 million.
  • The largest annual shift saw Consolidated Net Income soared 189.78% in 2023 before it crashed 333.26% in 2024.
  • A 5-year view of Consolidated Net Income shows it stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then skyrocketed by 189.78% to $31.1 million in 2023, then crashed by 333.26% to -$72.4 million in 2024, then surged by 32.09% to -$49.2 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Consolidated Net Income are -$49.2 million (Q3 2025), -$11.5 million (Q2 2025), and -$69.8 million (Q1 2025).